This blog is Part One. Part Two, entitled “Why Do I Write This Website?’ will be forthcoming. I am sure most of you have heard about the Rev. Billy Graham. In 2018, his daughter, Anne Graham Lotz, also a noted speaker and teacher, was diagnosed with breast cancer. She writes about enduring surgery, “seven brutal more »
In a recent study, investigators reported the findings of a clinical trial designed to compare the rates for detecting recurrent cancer sites using the prostate-specific membrane antigen (PSMA) PET-CT imaging agent (68Ga-PSMA-11) to those of 18F-fluciclovine in a group of men with recurrent prostate cancer who had already undergone prostatectomy and had very low levels more »
The U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of men with metastatic, castration (hormone)-sensitive prostate cancer (mCSPC), or those whose cancer still responds to androgen deprivation (hormonal) therapy (ADT). The decision is based on the double-blind TITAN Phase 3 trial (NCT02489318), as it showed that adding Janssen’s Erleada to more »
Tumors with large numbers of prostate cancer cells with mutations in DNA repair genes (e.g. BRCA1 and 2) are easier to target using prostate-specific membrane antigen (PSMA) therapies, and patients with these tumors are more likely to respond to this potential treatment’s use, a study found and published in European Urology. PSMA is a membrane more »
Men with metastatic hormone-resistant prostate cancer (mCRPC) given Lynparza® (olaparib), a breast and ovarian cancer treatment, lived a clinically meaningful longer time without disease progression or death compared to those given standard treatment with Xtandi® (enzalutamide) or Zytiga® (abiraterone) in a Phase 3 trial. These eligible patients had a mutation in one of 15 DNA more »
In a Phase 2/3 OSPREY clinical trial aimed at examining its diagnostic accuracy, 18F-DCFPyl (PyL), a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical trial data show. The tracer — developed by Progenics — is a more »
Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin (18F-fluciclovine) tracer, a Phase 2 trial shows. The results were presented at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held more »
This website is normally directed toward men with prostate and other medical issues. But I found this blog and the succeeding one to be very applicable to many other life’s problems. Isaiah 41:10 cites one of the clearest and most powerful promises God makes to those who have put their trust in Him as His more »
God’s promises e.g. Isaiah 41:10, apply to us who have a personal relationship with Him through faith in Jesus Christ. Within the Christian experience, there is a two-fold sense of peace. We are promised the peace of God when we commit our troubles and requests to Him, peace that will guard our heart and mind more »
The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO). The ENZAMET trial tested the drug enzalutamide (Xtandi) and the TITAN trial tested apalutamide (Erleada) in men whose cancer more »
Here is the 2019 guide from the Prostate Cancer Foundation. Section One deals with General Information and Medical Basics. Section Two provides valuable information for those who are newly diagnosed. Section Three describes treatment options for localized or locally advanced prostate cancer. Section Four discusses aspects of living with and after prostate cancer. This guide more »
Earlier this year, a series of informative videos dealing with several prostate cancer topics were produced by the Prostate Cancer Research Institute (PCRI). These included:\ 1. The Best Prostate Cancer Diet by Dr. Mark Moyad; 2. HDR Brachytherapy (temporary seeds) for Intermediate Risk by Dr. Mark Scholz: 3. How Immune Therapy Works to Treat Prosate more »
A recent study presented on May 3-6 at the American Urological Association’s 2019 Meeting found that treating metastatic, hormone-resistant prostate cancer (mCRPC) patients (who had not received chemotherapy) with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate). While therapies that lower male sex hormones (testosterone) — required for more »
I have not made such a request before on this website, however a situation has arisen with a good friend. Jim (not his real name) is a 60 years old man with advanced prostate cancer. He has received a number of customary treatment options none of which have curtailed the cancer. He is currently seeking more »
I was raised by wonderful Christian parents who took me to church regularly. I learned about God, Jesus, and well-known Biblical characters such as Noah, Moses, David, Jonah etc. This served as a good moral foundation but at one point, I realized that I knew about God and Jesus intellectually but did not know Him more »
I am grateful for all of you who subscribe to receive my blogs by email the day after they are posted. However, it has come to my attention that on occasion the Godandprostate blogs end up in spam instead of my inbox. It has happened to me on a few occasions. Therefore, please check your more »
Treatment with the radioactive molecule lutetium-177-PSMA-617 (LuPSMA), which binds to the prostate-specific membrane antigen, is a potential therapeutic strategy for patients with metastatic castration (hormone)-resistant prostate cancer (CRPC), results from a Phase II pilot study suggest. Prostate-specific membrane antigen (PSMA) is found at high levels in prostate cancers, particularly in patients with hormone-resistant disease — more »
Results from a Phase 3 clinical trial reveal that adding the androgen receptor inhibitor darolutamide to androgen deprivation (hormone) therapy (ADT) extends by 22 months the time men with hormone-resistant prostate cancer live without metastasis and without increasing the incidence of adverse events. The treatment also extended survival, time to pain progression, time until chemotherapy was needed, and kept patients more »
I recently received an e mail from the Cancer Treatment Centers of America (CTCA) entitled Health, Hope and Inspiration. These periodic e mails contain 30 minute interviews with Rev. Percy McCray, spiritual coordinator for CTCA. The latest interview entitled “Can God Use Cancer?” grabbed my attention. Rev. McCray’s immediate answer to the question was a more »
In Psalm 55:16-17, King David says “As for me, I shall call upon God, and the Lord will save me. Evening, morning and at noon, I will complain and murmur, and He will hear my voice.” God’s ears are open to our cries and His shoulders are wide enough to carry our burdens. He is more »